NanoSphere Health Sciences Valuation
Is 2CG undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 2CG when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate 2CG's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate 2CG's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 2CG?
Key metric: As 2CG is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.
| What is 2CG's PB Ratio? | |
|---|---|
| PB Ratio | -0.2x |
| Book | -US$1.63m |
| Market Cap | US$256.60k |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | n/a |
| Enterprise Value/EBITDA | n/a |
| PEG Ratio | n/a |
Price to Book Ratio vs Peers
How does 2CG's PB Ratio compare to its peers?
| Company | Forward PB | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 5.1x | ||
B8FK Biofrontera | 0.9x | n/a | €16.1m |
SBX SynBiotic | 1.8x | 107.0% | €27.9m |
HIGH Cantourage Group | 1.3x | 112.7% | €57.6m |
0RX Redx Pharma | 16.6x | -22.3% | €65.0m |
2CG NanoSphere Health Sciences | n/a | n/a | €359.6k |
Price-To-Book vs Peers: 2CG has negative equity and a Price-To-Book Ratio (-0.2x) compared to the peer average (5.1x).
Price to Book Ratio vs Industry
How does 2CG's PB Ratio compare vs other companies in the European Pharmaceuticals Industry?
| 11 Companies | Price / Book | Estimated Growth | Market Cap |
|---|---|---|---|
| 11 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Book vs Industry: 2CG has negative equity and a Price-To-Book Ratio (-0.2x) compared to the European Pharmaceuticals industry average (2.2x).
Price to Book Ratio vs Fair Ratio
What is 2CG's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PB Ratio | -0.2x |
| Fair PB Ratio | n/a |
Price-To-Book vs Fair Ratio: Insufficient data to calculate 2CG's Price-To-Book Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Teva Pharmaceutical Industries
US$18.8b
Develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally.
TEV
US$15.55
7D
-4.0%
1Y
78.7%
Collegium Pharmaceutical
US$1.0b
A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.
354
US$29.60
7D
5.7%
1Y
27.6%
Pharming Group
€491.5m
A biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally.
PHGN
€0.70
7D
-0.7%
1Y
-34.1%